Targeting protein kinases benefits cancer immunotherapy.
Biochim Biophys Acta Rev Cancer
; 1877(4): 188738, 2022 07.
Article
in En
| MEDLINE
| ID: mdl-35660645
ABSTRACT
Small-molecule kinase inhibitors have been well established and successfully developed in the last decades for cancer target therapies. However, intrinsic or acquired drug resistance is becoming the major barrier for their clinical application. With the development of immunotherapies, in particular the discovery of immune checkpoint inhibitors (ICIs), the combination of ICIs with other therapies have recently been extensively explored, among which combination of ICIs with kinase inhibitors achieves promising clinical outcome in a plethora of cancer types. Here we comprehensively summarize the potent roles of protein kinases in modulating immune checkpoints both in tumor and immune cells, and reshaping tumor immune microenvironments by evoking innate immune response and neoantigen generation or presentation. Moreover, the clinical trial and approval of combined administration of kinase inhibitors with ICIs are collected, highlighting the precise strategies to benefit cancer immune therapies.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Protein Kinases
/
Neoplasms
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
Biochim Biophys Acta Rev Cancer
Year:
2022
Document type:
Article
Affiliation country:
China